Key result
Ivabradine successfully suppressed ventricular arrhythmias in a patient with severe catecholaminergic polymorphic ventricular tachycardia refractory to conventional therapies.
Why the study?
Conventional treatments for CPVT can be inadequate and ICD use carries risks including electrical storm, prompting evaluation of alternative therapies such as ivabradine.
Does ivabradine suppress ventricular arrhythmias in a patient with refractory CPVT?
Case Report (n=1)
Does ivabradine suppress ventricular arrhythmias in a patient with refractory CPVT?
Ivabradine may serve as an effective add-on therapy for suppressing ventricular arrhythmias in patients with CPVT who are refractory to or intolerant of conventional treatments.
ICD use in CPVT warrants caution due to storm risk; leaves open optimal patient selection and alternatives.
Conventional treatment strategies for catecholaminergic polymorphic ventricular tachycardia (CPVT) include avoidance of strenuous exercise and competitive sports, drugs such as ß‐blockers and flecainide and, cervical sympathectomy. An implantable cardioverter‐defibrillator (ICD) has been utilized if the response to these strategies is inadequate; however, ICD use in CPVT patients, in addition to usual complications, is associated with an increased risk of life‐threatening electrical storm. Ivabradine is a selective inhibitor of hyperpolarization‐activated cyclic nucleotide‐gated potassium channel 4 generated funny current (If), which has been shown to be efficacious in suppression of inappropriate sinus tachycardia, junctional tachycardia, atrial tachycardia, and ventricular ectopy in humans. We report an 18‐year‐old male with a severe CPVT phenotype refractory to flecainide, nadolol, and sympathectomy who exhibited suppression of ventricular arrhythmias after initiation of ivabradine. These findings are of importance as ivabradine could be an important add‐on therapy in CPVT patients who are drug refractory or are unable to continue conventional therapies at the recommended doses.
No takes yet. Share an insight, caveat, or question.
Kohli et al. (2020) conducted a case report in Catecholaminergic polymorphic ventricular tachycardia (CPVT) (n=1). Ivabradine was evaluated on Suppression of ventricular arrhythmias. Ivabradine successfully suppressed ventricular arrhythmias in a patient with severe catecholaminergic polymorphic ventricular tachycardia refractory to conventional therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: